Bladder cancer "adjuvant-lite": Tastes great (works as well) and less filling (less toxic)? Journal Article


Authors: Galsky, M. D.; Scher, H. I.
Article Title: Bladder cancer "adjuvant-lite": Tastes great (works as well) and less filling (less toxic)?
Keywords: cancer chemotherapy; cancer survival; treatment response; clinical trial; cisplatin; doxorubicin; dose response; drug withdrawal; monotherapy; side effect; treatment planning; note; adjuvant therapy; chemotherapy, adjuvant; methotrexate; antineoplastic agent; metastasis; controlled clinical trial; multiple cycle treatment; kidney disease; mucosa inflammation; randomized controlled trial; antineoplastic combined chemotherapy protocols; peripheral neuropathy; editorial; combination chemotherapy; cyclophosphamide; dose-response relationship, drug; bladder cancer; cancer therapy; bladder tumor; urinary bladder neoplasms; vinblastine; febrile neutropenia; death; adjuvant chemotherapy; cystectomy; clinical research; epirubicin; drug substitution; transitional cell carcinoma; hearing loss; m vec protocol; m-vec protocol
Journal Title: Journal of Clinical Oncology
Volume: 23
Issue: 22
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2005-08-01
Start Page: 4823
End Page: 4826
Language: English
DOI: 10.1200/jco.2005.92.001
PUBMED: 15939919
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 3" - "Export Date: 24 October 2012" - "CODEN: JCOND" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew Galsky
    29 Galsky
  2. Howard Scher
    1130 Scher